Search

Your search keyword '"Ingiliz P."' showing total 290 results

Search Constraints

Start Over You searched for: Author "Ingiliz P." Remove constraint Author: "Ingiliz P."
290 results on '"Ingiliz P."'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

4. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

5. Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study

6. Hepatitis A outbreak among MSM in Berlin due to low vaccination coverage: Epidemiology, management, and successful interventions

7. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.

8. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

9. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

10. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

15. Assessment of liver fibrosis: Noninvasive means

16. Impact of an add-on strategy of the C-C chemokine receptor 5 (CCR5) antagonist maraviroc on hepatic inflammation in HIV-infected individuals with non-alcoholic steatohepatitis: a paired-liver biopsy proof-of-concept study

19. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.

20. Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B

25. Increased BMI and Type 2 diabetes are the main predictors of NAFLD and advanced fibrosis in liver biopsies of patients with HIV mono-infection

26. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

27. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load.

28. Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load.

29. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

31. PNPLA3 and HSD17B13 gene variants exert opposite effects on fatty liver phenotypes: results from the FLAG cohort

32. Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results from the ECHAM study

33. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

34. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

36. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy

37. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

38. Effects of the common PNPLA3 p.I148 M polymorphism on the fatty liver phenotypes in German patients: results from the FLAG “real life” cohort

39. Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study

40. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

41. Baseline patient characteristics of the German multicentric prospective real-world NAFLD cohort: The Fatty Liver Assessment in Germany (FLAG) study

42. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): The 'Real-life Setting' proves the concept

43. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

47. Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy – are all HCV subpopulations treated similarly? – Results from the German hepatitis C Cohort

48. Can HCV be eliminated among HIV-infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates

49. Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany?

50. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection

Catalog

Books, media, physical & digital resources